Ozempic economics: How GLP-1s will disrupt the economy in 2025
A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...
News Nation on MSN6d
FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...
Yahoo6d
FDA approves Zepbound for sleep apnea in obese adults
In addition, those who took Zepbound saw their body weight decrease significantly compared to those who were on a placebo. The FDA says side effects for Zepbound include nausea, diarrhea ...
Verywell Health on MSN3d
Zepbound Gets FDA Approval to Treat Sleep Apnea
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...
FiercePharma3d
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.
Arizona Couple Details 'Life-Changing’ Experience on Weight Loss Drugs — Including ‘Sulfur Burps’ (Exclusive)
Arizona couple Michael and Julie Carroll have lost a combined 177 lbs. on a GLP-1 weight loss drug. 'It gave me my ...
Forbes4d
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.
Yahoo Finance3d
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...